The combination of disitamab vedotin with toripalimab generated responses and displayed a manageable safety profile in patients with locally advanced or metastatic urothelial carcinoma, irrespective of HER2 expression.
Favorable preliminary safety and efficacy data for anti-BTLA monoclonal antibody, icatolimab, for the treatment of lymphoma and solid tumors Toripalimab continues to demonstrate synergy as the